Cognition Therapeutics, Inc. (CGTX)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Ms. Lisa Ricciardi
|
CEO, President & Director | 1.06M | -- | 1960 |
|
Mr. John Brendan Doyle
|
Chief Financial Officer | 681.53k | -- | 1977 |
|
Dr. Anthony O. Caggiano M.D., Ph.D.
|
Chief Medical Officer | 742.63k | -- | 1970 |
|
Dr. Steven A. Weissman Ph.D.
|
VP & Head of CMC | -- | -- | -- |
|
Ms. Anita Cornet
|
Head of Quality | -- | -- | -- |
|
Mr. Bobby Horn
|
Corporate Controller | -- | -- | -- |
Cognition Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
